Analyse

Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung

#HIV therapeutics ×

1. Sept. 2026•1 Min. Lesezeit

ST Pharm projected Q2 earnings beat expectations on oligonucleotide sales

ST Pharm is forecast to post Q2 revenue of 103.4 billion KRW and operating profit of 20.8 billion KRW, up 51.5% and 60.8% YoY, driven by oligonucleotide shipments and new orders.